Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05203354 Completed - Psoriasis Clinical Trials

Omentin-1 Level in Psoriatic Patients Treated With Narrowband Ultraviolet B Phototherapy Versus Acitretin

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

Studying the effects of Narrowband Ultraviolet B versus acitretin on psoriatic patients

NCT ID: NCT05203315 Not yet recruiting - Plaque Psoriasis Clinical Trials

Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

Start date: January 17, 2022
Phase: Phase 3
Study type: Interventional

This study seeks to evaluate the safety, tolerability, and efficacy of topical Duobrii® Lotion in adult subjects with mild plaque psoriasis.

NCT ID: NCT05200598 Recruiting - Clinical trials for Cardiovascular Diseases

Cardiovascular Risk Predictors in Patients With Psoriasis

Start date: October 1, 2021
Study type: Observational

The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

NCT ID: NCT05200247 Not yet recruiting - Clinical trials for Generalized Pustular Psoriasis

An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

Start date: February 1, 2022
Phase: Phase 3
Study type: Interventional

This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no alternative treatment options. Participants get a single infusion of spesolimab into a vein. They can get another spesolimab infusion one week after the first infusion if the doctors think it is helpful. Participants are in the program for about 4 months and visit the study site about 5 to 6 times. The doctors regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT05194839 Recruiting - Clinical trials for Palmoplantar Pustulosis

A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)

Start date: January 5, 2022
Phase: Phase 2
Study type: Interventional

A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

NCT ID: NCT05190419 Recruiting - Psoriasis Clinical Trials

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

Start date: December 30, 2021
Phase: Phase 2
Study type: Interventional

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe plaque-type psoriasis and assess the safety aspects of these 3 different doses.The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.

NCT ID: NCT05185258 Not yet recruiting - Psoriasis Clinical Trials

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

Start date: January 1, 2022
Phase: Phase 4
Study type: Interventional

Psoriasis is a non-communicable chronic immune-mediated disease. Psoriatic skin is characterized by excessive proliferation of skin cells and infiltration of immune cells. The cause of psoriasis is so far unknown. Established therapeutics include topical, oral-systemic, biologic, narrow-band ultraviolet B (NB-UVB). A persistent antipsoriatic effect by the newest biologic therapies has been demonstrated after treatment discontinuation. However, the remittive hallmark of psoriasis suggests the existence of a molecular scar, a kind of disease memory, in clinically healed skin. It has been suggested that this disease memory can be attributed to the tissue-resident memory T (TRM) cell. The main purpose of the study is to investigate whether (NB-UVB) treatment and concomitant Enstilar® treatment can change the amount of TRMs in the skin as well as change the expression in the microenvironment around these cells in the skin from psoriasis patients. In addition, the investigators will investigate whether the treatment can change the quantity and types of other psoriasis-related cells in the skin. In addition to this, the investigators will also examine the effect of treatment on patient-related parameters.

NCT ID: NCT05184699 Not yet recruiting - Psoriasis Clinical Trials

The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The food supplement Endocalyx is considered to support the endothelial glycocalyx integrity by supplying sulfated polysaccharides, anti-oxidant enzymes and additional substrates for glycocalyx synthesis. The investigators will study the effect of Endocalyx on endothelial, vascular and left ventricular myocardial function in patients with psoriatic disease.

NCT ID: NCT05184348 Active, not recruiting - Psoriasis Vulgaris Clinical Trials

Plexin B2 Gene Expression and Polymorphisms in Psoriasis : Relation to Narrow Band Ultraviolet B , Acitretin and Combined Therapy

Start date: November 23, 2021
Phase: Phase 4
Study type: Interventional

Patients will be randomly assigned (1:1:1 ) either to ; NB-UVB photo-therapy alone , Acitretin therapy alone or NB-UVB photo-therapy combined with Acitretin therapy randomization will be done by closed envelopes . investigator will be blinded to study drug assignment , while patients and data interpreter will not be masked to study drug assignment.

NCT ID: NCT05174598 Completed - Clinical trials for Mild to Moderate Plaque Psoriasis

A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis

Start date: October 3, 2018
Phase: Phase 3
Study type: Interventional

This study is a Phase III, multicentre, randomized, observer blind, parallel group, three arms, controlled clinical trial to evaluate the efficacy and safety of topically applied Calcipotriol/AKVANO 50 μg/g cutaneous solution against Calcipotriol Ointment 50 micrograms/g, Sandoz and placebo in patients with mild to moderate plaque psoriasis